@article{038ae9dc6c934df29f4f5ca132be955d,
title = "TARGETING THE DYSMETABOLIC SYNDROME IN A CARDIOVASCULAR DISEASE DIABETIC COHORT WITH ROSIGLITAZONE: 1 YEAR ANALYSIS: 85",
author = "M. Aguinaldo and D. Kronstad and C. Cole and A. Lyko and E. Chao and S. Daud and S. Krishnamoorthy and K. Vu and W. Liu and R. Magbual and J. Petrofsky and Lee, \{Scott W.\}",
note = "Purpose The insulin sensitizer rosiglitazone (RSG) has been shown to improve endothelial function and reduce vascular inflammation. However, no study has prospectively looked at its overall effect on cardiovascular events. Methods This was a non-randomized open label prospective parallel pilot study. Patients with known coronary artery disease, dysmetabolic syndrome and type 2 diabetes were recruited for the study.",
year = "2005",
month = jan,
day = "1",
language = "American English",
volume = "53",
pages = "S92.4--S92",
journal = "Journal of Investigative Medicine",
number = "1",
}